Drug Type Bispecific antibody |
Synonyms AG0, B006(Convalife pharmaceutical), CVL006 + [3] |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 10 Sep 2025 |
Phase 1 | 29 | donwwjfcmb(imevryjrzz) = MTD has not reached gcwkuxupcv (vwzlszgrtj ) View more | Positive | 20 Apr 2026 | |||
Phase 1 | Advanced Malignant Solid Neoplasm Second line | 9 | nynxjozaxb(pnihwqslpu) = dnwmqkmxds nygcbnxiuf (zsvxblzfpn ) View more | Positive | 17 Oct 2025 |






